Jade Biosciences (JBIO) Study update summary

Program Overview and Milestones

• JADE301 is a fully human, half-life-extended anti-IFN-β monoclonal antibody targeting dermatomyositis, a severe autoimmune disease with high unmet need.

• Phase 1 placebo-controlled, single ascending-dose study in 24 healthy volunteers is planned for Q4 2026, with interim data anticipated in the second half of 2027.

• JADE301 is part of a pipeline including JADE101 and JADE201, all licensed from Paragon Therapeutics.

• The company is well-funded with a cash runway into Q4 2028, supporting multiple upcoming milestones.

Disease Background and Unmet Need

• Dermatomyositis affects approximately 50,000 adults in the U.S., causing significant morbidity and functional impairment.

• 60–80% of patients do not achieve sustained remission, and mortality is about three times higher than the general population.

• Most patients experience pain, require opioids, and have frequent disease flares despite current therapies.

• There is a continued need for targeted, disease-modifying, and steroid-sparing therapies with durable control and convenient dosing.

Scientific Rationale and Mechanism

• IFN-β is a key driver of dermatomyositis pathology, with overactive type I interferon signaling in skin and muscle.

• Selective IFN-β inhibition has shown clinical proof-of-concept in both muscle and skin components of the disease.

• Dazukibart, an anti-IFN-β antibody, demonstrated strong efficacy and safety in Phase 2 trials, validating the target.